A number of other equities research analysts have also issued reports on NTLA. Zacks Investment Research lowered shares of Intellia Therapeutics from a hold rating to a sell rating in a research note on Tuesday, May 7th. Roth Capital began coverage on shares of Intellia Therapeutics in a research note on Monday. They set a neutral rating and a $16.00 target price for the company. Evercore ISI began coverage on shares of Intellia Therapeutics in a research note on Thursday, April 11th. They set an outperform rating for the company. Chardan Capital reissued a buy rating and set a $57.50 target price on shares of Intellia Therapeutics in a research note on Wednesday, February 27th. Finally, Wedbush raised shares of Intellia Therapeutics from a neutral rating to an outperform rating and lifted their target price for the company from $20.00 to $21.00 in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $27.36.
Shares of NASDAQ:NTLA traded down $0.23 during trading on Thursday, reaching $14.16. 37,665 shares of the company traded hands, compared to its average volume of 398,589. The firm has a market capitalization of $647.25 million, a P/E ratio of -7.15 and a beta of 2.58. Intellia Therapeutics has a 1-year low of $11.03 and a 1-year high of $32.95. The company has a quick ratio of 7.74, a current ratio of 7.74 and a debt-to-equity ratio of 0.06.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, May 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. The company had revenue of $10.43 million during the quarter, compared to analyst estimates of $9.43 million. Intellia Therapeutics had a negative net margin of 257.28% and a negative return on equity of 31.68%. The company’s revenue for the quarter was up 39.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.51) EPS. Equities research analysts expect that Intellia Therapeutics will post -2.43 earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in the stock. Ameritas Investment Corp acquired a new position in shares of Intellia Therapeutics in the first quarter valued at about $28,000. Tortoise Investment Management LLC increased its holdings in shares of Intellia Therapeutics by 100.0% in the first quarter. Tortoise Investment Management LLC now owns 2,000 shares of the company’s stock valued at $34,000 after purchasing an additional 1,000 shares during the period. Quantamental Technologies LLC increased its holdings in shares of Intellia Therapeutics by 1,170.4% in the first quarter. Quantamental Technologies LLC now owns 3,303 shares of the company’s stock valued at $56,000 after purchasing an additional 3,043 shares during the period. Nikko Asset Management Americas Inc. increased its holdings in shares of Intellia Therapeutics by 20.0% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 5,980 shares of the company’s stock valued at $82,000 after purchasing an additional 995 shares during the period. Finally, Resources Investment Advisors Inc. acquired a new position in shares of Intellia Therapeutics in the first quarter valued at about $92,000. 74.34% of the stock is owned by institutional investors and hedge funds.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
Featured Story: Stop Order Uses For Individual Investors
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.